Cargando…
Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer
Nivolumab is an immune checkpoint inhibitor with demonstrated efficacy against several malignant tumors. Alterations in driver oncogenes such as EGFR and ALK are a poor prognostic factor in nivolumab therapy for non-small cell lung cancer (NSCLC), whereas a smoking history is a well-known, favorable...
Autores principales: | Yamasaki, Masahiro, Saito, Naomi, Hada, Yu, Miyamoto, Sayaka, Okanobu, Hideharu, Ikeda, Naoya, Daido, Wakako, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436064/ https://www.ncbi.nlm.nih.gov/pubmed/28559820 http://dx.doi.org/10.1159/000470830 |
Ejemplares similares
-
A Rare Combination of Dermatomyositis, Interstitial Pneumonia, and Lung Cancer in a Patient Treated with Immunosuppressive Therapy and Chemotherapy
por: Daido, Wakako, et al.
Publicado: (2017) -
First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017) -
A bronchial fibroepithelial polyp with abnormal findings on auto‐fluorescence imaging
por: Saito, Naomi, et al.
Publicado: (2017) -
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017) -
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018)